Biotechnology company Entera Health reported on Thursday the receipt of the IRB approval to commence a clinical trial in Barcelona Spain using EnteraGam to manage the symptoms associated with COVID-19 infections in partnership with Lemus Buhils.
The companies said EnteraGam (a serum-derived bovine immunoglobulin/protein isolate, SBI) is a medical food product intended for the dietary management of chronic diarrhea and loose stools. It is administered under medical supervision in the USA.
Titled "Randomized Open-Label Clinical Study Evaluating the Impact of EnteraGam, a Nutritional Intervention containing Bovine Plasma-Derived Immunoglobulin CoNcentrate, on Clinical Outcomes In People with COVID-19 (Spanish PICNIC Study)" , the trial will investigate the use of EnteraGam to manage inflammation and symptom severity in patients with mild-to-moderate SARS-CoV-2 infections.
This randomized open-label Spanish PICNIC clinical trial aims to enroll 420 subjects with SARS-CoV-2 infection with mild-to-moderate symptom severity, including respiratory distress, coughing and shortness of breath. The primary endpoints of the trial are the change in plasma IL-6 levels between entry and the percentage of patients with disease progression by Week two, concluded the partnership.
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP